Latest Regulatory News

Recce Pharmaceuticals has expanded its intellectual property footprint with a newly granted patent in Brazil, protecting its innovative synthetic anti-infectives against a broad range of infections. This milestone strengthens Recce’s position in one of South America’s largest antibiotic markets.

Coles Group Limited has updated its dividend details, confirming a fully franked 41 cent per share payout for the half-year ending January 2026, alongside a Dividend Reinvestment Plan price set at $21.32.

Klevo Rewards partners with Bybit to launch KLVAUD, an Australian dollar-backed stablecoin integrated with a Mastercard and a global rewards ecosystem. This move aims to transform everyday spending into digital asset rewards accessible worldwide.

Native Mineral Resources (ASX: NMR) has updated its drilling results at the Podosky deposit in Queensland, confirming shallow, high-grade gold mineralisation that supports near-term open-pit mining plans. Mining activities are targeted to commence in April 2026.

Avira Resources has validated significant high-grade gold intersections at its Mt Cattlin Gold Project, underpinning plans for a maiden Mineral Resource Estimate by the end of 2026. The company is poised to commence drilling in Q2 to test extensions across multiple prospects.

Emyria Limited is on track to open its first Empax clinic in Victoria by Q2 2026, having secured key operational milestones including a trained clinical workforce and dual reimbursement pathways.

Latrobe Magnesium Limited has successfully produced around 20 tonnes of high-grade Magnesium Oxide from its Hazelwood North Demonstration Plant, paving the way for magnesium metal production later this year.

BlinkLab has enrolled its first participant in the pivotal FDA 510(k) validation study for its autism diagnostic aid, BlinkLab Dx1, aiming for regulatory submission by the end of 2026.

Radiopharm Theranostics reports promising second interim Phase 2b results for RAD 101, showing 90% concordance with MRI in detecting brain metastases and encouraging sensitivity and specificity trends.

dorsaVi has commenced development of Sensor V6.5, a firmware upgrade that embeds intelligence directly within its wearable sensors, reducing latency and paving the way for future neuromorphic computing integration.

Echo IQ has strengthened its partnership with Mayo Clinic to distribute its AI-driven heart failure diagnostic tool, EchoSolv HF, pending FDA clearance. The expanded agreement offers a scalable commercial pathway across a vast US hospital network.

Latitude Group Holdings Limited has launched an offer to raise approximately $100 million through Capital Notes 2, a new series of perpetual, subordinated, unsecured convertible notes. Existing Capital Notes 1 holders are invited to reinvest in the new notes, which feature discretionary quarterly distributions and potential conversion to ordinary shares.